TRT bloodwork: what and when

The injection is the easy part. The labs are what actually tell you whether your dose is right and whether your body is handling it well — and timing them wrong can send you chasing a number that was never real to begin with.

Short answer: before the first dose, get total testosterone (two early-morning draws), hematocrit and hemoglobin, PSA if you are over 40, LH and FSH, and a lipid panel.^1,2 Most prescribers recheck testosterone and hematocrit about 6–8 weeks after you start or change the dose, with blood drawn midway between injections for cypionate or enanthate.¹ Once your results are stable, both major guidelines move to testing every 6–12 months.^1,2

Testosterone replacement therapy (TRT) is a prescription treatment that gets dosed against bloodwork, not against how you feel in week two. The Endocrine Society's clinical practice guideline on testosterone therapy is explicit that treatment should be monitored with scheduled lab draws, not adjusted on a whim between visits¹. That matters because the two things bloodwork actually protects — your red blood cell count and your prostate — don't reliably announce themselves with symptoms until a problem is already established. This guide covers which markers matter, when to test them, and how to read what comes back. For the injection technique itself, see our SubQ vs IM testosterone guide; for what to expect over the following months, see our TRT results timeline. Two markers have their own guides: high hematocrit on TRT (thresholds and what prescribers do about it) and estradiol on TRT (assays, symptoms and the evidence on aromatase inhibitors).

TRT bloodwork schedule at a glance

Baseline labs before starting TRT

Before the first injection, both the Endocrine Society guideline and the American Urological Association (AUA) guideline on testosterone deficiency call for the same core baseline panel^1,2:

1. Total testosterone — measured on two separate early-morning fasting draws, since a single low reading isn't considered diagnostic on its own
2. Hemoglobin and hematocrit — to confirm you're not already elevated before a drug that raises red blood cell count enters the picture
3. PSA (prostate-specific antigen) — required by the AUA guideline in men over 40 before starting therapy, to rule out an existing prostate cancer signal²
4. LH and FSH — to help distinguish primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism, which can change the treatment plan
5. A lipid panel — as a reference point, since testosterone can shift cholesterol values over time

This baseline isn't paperwork — it's the number every later result gets compared against. A hematocrit of 48% six months into therapy means something different if your baseline was 41% versus 47%.

The 6–8 week follow-up: what to test and why

Testosterone cypionate and enanthate, the two esters used in most injectable TRT, have half-lives around 7–8 days, and it takes roughly four to five half-lives — about six to eight weeks — for blood levels to reach a stable, predictable pattern after starting or changing a dose. Testing sooner just measures a level that's still moving. The Endocrine Society guideline calls for evaluating symptoms, side effects, and drawing testosterone and hematocrit within the first year of treatment, with the specific practice of an early follow-up draw widely used by prescribers to confirm the dose is landing in range before the next adjustment¹. The AUA guideline frames it similarly: an initial follow-up level "after an appropriate interval to ensure that target testosterone levels have been achieved," then testosterone checked every 6–12 months thereafter².

At this visit, most prescribers repeat total testosterone, hematocrit, and (depending on symptoms or baseline estradiol) estradiol. PSA gets rechecked at the AUA-recommended 3–12 month mark in men over 40, not necessarily at the 6–8 week draw itself².

Draw timing: why when you draw blood matters as much as what you test

A testosterone level drawn 24–48 hours after an injection — near the peak — can read substantially higher than the same person's level drawn right before their next dose, at the trough. Because injectable esters produce a peak-and-decline curve rather than a flat line, the Endocrine Society guideline fixes the timing: for testosterone cypionate or enanthate, measure midway between injections and adjust the dose or frequency if that mid-interval level is above 600 ng/dL or below 350 ng/dL; for testosterone undecanoate, measure at the end of the dosing interval, just before the next injection¹. In practice, that means:

1. On weekly cypionate or enanthate, midway between injections means roughly 3–4 days after your shot
2. On twice-weekly or every-other-day schedules, draw at the same point in your cycle each time and tell your prescriber when your last dose was
3. Keep the interval between your last injection and the blood draw consistent across visits, so results are actually comparable to each other

Key markers, explained

Total and free testosterone

Total testosterone measures everything in circulation — bound and unbound. But only the unbound fraction, free testosterone (roughly 1–2% of the total), is available to act on tissue directly; most of the rest is tightly bound to sex hormone-binding globulin (SHBG), with a smaller amount loosely bound to albumin³. A landmark reappraisal of testosterone-SHBG binding in Endocrine Reviews found that free testosterone measurement becomes particularly valuable when total testosterone sits in a borderline range, or when a condition affecting SHBG (thyroid disease, obesity, liver disease, aging) makes total testosterone an unreliable stand-in for what's actually reaching tissue³. The Endocrine Society guideline recommends checking free testosterone by equilibrium dialysis, or a validated calculation from total T and SHBG, whenever a condition known to alter SHBG is present¹.

SHBG

SHBG itself is worth tracking less as a target and more as context — it's the variable that determines how much of your total testosterone number is actually meaningful. High SHBG (common with aging, hyperthyroidism, or some anticonvulsants) can make total testosterone look adequate while free testosterone runs low; low SHBG (common with obesity, hypothyroidism, or high-dose glucocorticoids) can do the reverse. If your total T and how you feel don't seem to line up, SHBG is usually the missing piece your prescriber checks next.

Estradiol (E2)

Testosterone aromatizes into estradiol, so E2 rises along with testosterone on therapy — that's expected, not a side effect on its own. Problems show up at the extremes: too little estradiol can affect bone density, libido, and joint comfort, while too much is linked to water retention, gynecomastia, and mood symptoms in some men. A retrospective study of men managed with aromatase inhibitors for elevated estradiol on TRT used E2 above 60 pg/mL regardless of symptoms, or 40–60 pg/mL with symptoms, as the practical trigger for intervention, titrating back down toward a 20–40 pg/mL range⁴. Those cutoffs come from one clinical cohort's practice rather than a formal society guideline — there is no universal consensus threshold for E2 in men on TRT — but they reflect how estradiol is actually being managed in practice today.

Hematocrit and hemoglobin

This is the marker most likely to force a dose change. Testosterone stimulates red blood cell production by raising erythropoietin and suppressing hepcidin, and that effect is dose-dependent — higher and more frequent dosing tends to push hematocrit up faster⁵. Elevated hematocrit (erythrocytosis) is more than a lab curiosity: a large observational body of evidence links testosterone-induced erythrocytosis to increased risk of major adverse cardiovascular events and venous thromboembolism, particularly in the first year of therapy⁵. The FDA prescribing information for injectable testosterone specifically calls out hemoglobin and hematocrit monitoring "to detect polycythemia" during long-term use⁶.

PSA

PSA doesn't measure testosterone's effect directly — it's a prostate-health check that rides along with TRT monitoring because testosterone can influence prostate tissue. The AUA guideline requires baseline PSA in men over 40 before starting therapy, then re-checks it at 3–12 months². The Endocrine Society guideline sets a specific referral bar during the first year: a confirmed PSA rise of more than 1.4 ng/mL above baseline, a confirmed PSA above 4.0 ng/mL, or a prostatic abnormality found on exam, any of which warrants a urology referral rather than a wait-and-see approach¹.

Lipids

A 2025 systematic review of TRT's cardiovascular effects found the overall lipid picture is mild and mixed: total cholesterol and LDL tended to decrease slightly across the studies reviewed, while HDL results varied — modestly higher, stable, or modestly lower depending on the formulation and dose used⁷. The FDA label for injectable testosterone notes cholesterol can rise during androgen therapy and lists it among the parameters worth periodic monitoring⁶. In practice, most prescribers recheck a lipid panel at the same 3–6 month follow-up as other labs and then fold it into annual monitoring once values look stable.

What "normal range" means once you're on TRT

The reference range on your lab report is built from a general population, not from men actively being dosed with testosterone — and "in range" isn't the same as "correctly dosed." The Endocrine Society guideline recommends aiming for testosterone concentrations in the mid-normal range during treatment, not the top of the range¹. A mid-interval level sitting at the very bottom of normal suggests under-dosing or a dose taken too infrequently for the ester's half-life; a level near or above the top of the range — especially paired with rising hematocrit — suggests the dose or frequency should come down, even if you feel good. "Feeling great" is not, on its own, a reason to skip the recheck that would catch a hematocrit or estradiol problem before it becomes symptomatic.

Red flags: when hematocrit or estradiol needs action

How often to retest after the first three months

Once your dose is stable and your first two or three follow-up draws look consistent, both major guidelines shift to a longer interval: testosterone and hematocrit roughly every 6–12 months, with PSA following standard age-based prostate cancer screening guidance after the first year^1,2. That interval resets, though, any time something changes — a new dose, a switch from weekly to twice-weekly injections, a change in injection route, or a new medication that could affect SHBG or hematocrit. Each of those warrants another 6–8 week check before settling back into the longer cadence. Our TRT results timeline covers roughly what to expect symptom-wise across that same first year, alongside the lab schedule.

Building your own bloodwork tracking routine

The single most common mistake isn't skipping labs — it's losing the thread between them. A testosterone level means little without knowing your dose, your injection route, and exactly when relative to your last shot it was drawn; a hematocrit trend matters more than any single hematocrit number. Keeping your labs, doses, and injection timing in one place — rather than scattered across portal PDFs and a notes app — is what actually lets you (and your prescriber) see a trend forming before it becomes a red-flag number. The TRT dose calculator can help you plan a protocol before you start; Peptide Me's tracker lets you log bloodwork results alongside your injection history on one timeline and export a doctor-ready summary, so your next appointment starts with a trend line instead of a stack of separate reports. Visit the TRT hub for the rest of our TRT guides.

Disclaimer: this article explains what TRT bloodwork typically covers and is not medical advice. Testosterone is a prescription, controlled medication, and the specific labs you need, how often you need them, and what any individual result means for your dose should come from the clinician managing your care — not from thresholds read online. If a result concerns you, contact your prescriber rather than waiting for your next scheduled visit.

FAQ

References

Primary sources — PubMed / NEJM / The Lancet.

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
2. American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. 2018 (reviewed and validity confirmed 2024). https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline
3. Goldman AL, Bhasin S, Wu FCW, Krishna M, Matsumoto AM, Jasuja R. A Reappraisal of Testosterone's Binding in Circulation: Physiological and Clinical Implications. Endocr Rev. 2017;38(4):302-324. https://pmc.ncbi.nlm.nih.gov/articles/PMC6287254/
4. Punjani N, Bernie H, Salter C, Flores J, Benfante N, Mulhall JP. The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sex Med. 2021;9(4):100378. https://pmc.ncbi.nlm.nih.gov/articles/PMC8360915/
5. Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified? Endocr Connect. 2024;13(10):e240283. https://pmc.ncbi.nlm.nih.gov/articles/PMC11466264/
6. DailyMed. DEPO-TESTOSTERONE (testosterone cypionate) injection, solution — Prescribing Information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cfbb53d4-b868-4a28-8436-f9112eb01c39
7. Ezeamii PC, Adebayo AA, Ozojide KO, et al. Cardiovascular Effects of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review of Lipid Profiles, Inflammatory Markers, and Vascular Function. Cureus. 2025;17(12):e99456. https://pmc.ncbi.nlm.nih.gov/articles/PMC12810209/